This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine
that could be a new way to treat cancer. A vaccine that could alert the immune system to the
presence of cancer cells in the body may enable the immune system to target and kill those
cells effectively. This vaccine is intended to work by making the immune system kill cells
that have a special protein (called 5T4) that is present on the surface of cancer cells. The
vaccine is made up of two recombinant viruses ("ChAdOx1" and "MVA") that have been designed
to produce the 5T4 protein and have been modified so that they are weakened and cannot
reproduce themselves within the body like normal viruses. Once injected into the body, these
viruses make the 5T4 protein and help the body's immune system to learn to target this
protein and destroy cancer cells.
This is a first-in-human study to evaluate the safety and immunogenicity of
ChAdOx1.5T4-MVA.5T4 vaccination regime. It is evaluated in neo-adjuvant setting in low and
intermediate risk localised prostate cancer patients who have either decided to have their
prostate removed or are stable on active surveillance.